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The development and functional consequences of cardiac
hypertrophy have long been a subject of intense interest;
this interest was recently heightened by the demonstration
that ventricular hypertrophy could be reversed by medical
therapy (I). The clinical impact of these observations was
further increased by the possibility of quantitating left ven-
tricular hypertrophy noninvasively by echocardiography and,
thus, of monitoring the effects of treatment on left ventric-
ular structure and function in patients (2,3). The Fra-
mingham studies have added a new dimension to the ques-
tion by stressing the role of systemic hypertension as a prime
cause of left ventricular hypertrophy (4) and by reporting




Studies from different centers succeeded each other rap-
idly and began to outline a picture of hypertensive left ven-
tricular hypertrophy that was different and more complex
than previously thought. Thus, the relation between hyper-
tension and left ventricular hypertrophy, usually thought of
as a direct response of the heart to a pressure overload, was
observed from both experimental and clinical studies to
involve more factors than blood pressure levels alone. In-
creases in left ventricular wall thickness and mass developed
early in the evolution of the disease, and could be made to
regress in relatively short periods with some, but not all,
forms of equipotent antihypertensive therapy. Ventricular
weight did not always correlate with arterial pressure levels;
the correlation was better with diurnal averages than with
single readings, but even then, the index of determination
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rarely exceeded 25 to 30% (6). Because of the poor prog-
nosis associated with electrocardiographic left ventricular
hypertrophy, and in view of the possibility of inducing its
regression by antihypertensive measures, evaluation of the
functional significance of increased left ventricular mass
became more urgent for the large numbers of patients with
hypertension. Is it a compensatory process to be left un-
disturbed, or does it bear the seeds of future decompensation
and constitute both an indication for treatment and deter-
minant of the choice of drugs?
The many questions raised by these rapid advances have
been addressed in many recent reviews (1,7,8) as well as
by Panidis et al. (9) in this issue of the Journal. An editorial
on the subject can, therefore, only underline some of the
still unanswered questions or point out current research di-
rections with potentially important clinical implications. In
this regard, it should also be noted that vascular hypertrophy
is an important component of the hypertensive process; the
pressure load is imposed on both the heart and the arterial
system. Studies of the hypertrophic responses of each could
benefit greatly from comparison of the results in both.
Multiple types of left ventricular hypertrophy. The
first point to be underlined is a caveat regarding simplified
or widespread extrapolations from one kind of experimental
conditions to cardiac hypertrophy in general. The hetero-
geneity of cardiac hypertrophy is now well recognized ( 10);
less well recognized perhaps is the presence of important
structural and functional differences within the same "type"
of hypertrophy (pressure overload). Indeed, recent studies
(3) have demonstrated a wide spectrum of variations in
hypertensive left ventricular hypertrophy (asymmetric, con-
centric or eccentric; inappropriate or inadequate to the load).
The susceptibility of cardiac function to increased afterload
or its dependence on adrenergic support also varied widely
among patients; the level of afterload was more of a dom-
inant factor when dilation was associated with hypertrophy
(3).
Electrocardiographic versus echocardiographic di-
agnosis. This multiplicity of types of hypertensive left ven-
tricular hypertrophy naturally raises a question about prog-
nostic conclusions reached mainly on the basis of
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sitivity and specificity of electrocardiographic signs of ven-
tricular hypertrophy have been widely investigated, as have
been the important pitfalls associated with voltage criteria
and their dependence on body build and placement of pre-
cordial electrodes. The conclusion that changes in precordial
voltage relate in some degree to changes in left ventricular
mass is a reasonable extrapolation from autopsy correla-
tions, but it has yet to be rigidly established. The superiority
of echocardiography in recognizing left ventricular hyper-
trophy and in allowing a quantitative direct determination
of left ventricular wall thickness and mass is widely rec-
ognized. Because the correlation in diagnostic power be-
tween the two methods favors echocardiography by a wide
margin, we should critically examine the implications of
those findings for therapy. Whether the serious prognosis
associated with the detection of electrocardiographic left
ventricular hypertrophy in patients with hypertension also
applies to the diagnosis of left ventricular hypertrophy by
echocardiographic criteria still remains to be determined.
Reversal of Left Ventricular Hypertrophy
Reversal of cardiac hypertrophy has definitely been dem-
onstrated in both patients and experimental animals (I), but
it has also been shown not to depend solely on reduction
of the ventricular pressure load. It does not necessarily occur
after otherwise successful surgery for aortic regurgitation
or stenosis, as noted by Panidis et al. (9). and it is not
closely related to blood pressure control in hypertensive
subjects. Among the latter, the degree of regression in left
ventricular mass varied with the type of antihypertensive
agent used (II), but it also differed from patient to patient
treated with the same drug (7). In some cases, there was
an obvious reason for the lack of regression, such as as-
sociated myocardial or coronary disease or lack of main-
tained blood pressure control. More often than not, how-
ever, no apparent cause was found. Although it has been
claimed that the greater the left ventricular mass before
treatment, the more marked the regression of hypertrophy,
exceptions are seen (6); it would be important to determine
whether treatment can indeed reduce the mass of a "nor-
mal" ventricle. One of the main factors interfering with
reversal of left ventricular hypertrophy during antihyper-
tensive therapy appears to be the reflex sympathetic stim-
ulation induced by some vasodilators (12-14). In summary,
both the development and regression of left ventricular hy-
pertrophy in response to variations in mechanical load are
obviously modulated by many factors such as age, sex,
adrenergic drive and humoral influences including the renin-
angiotensin system (1,15). To the degree that those factors
can be influenced by treatment and to the extent that reversal
of hypertrophy might appear a desirable goal, future choices
of therapy may be influenced by current research directed
to those factors and to the functional consequences of re-
duction in left ventricular mass.
Is Reversal of Cardiac
Hypertrophy Beneficial?
Left ventricular function. Whether regression of car-
diac hypertrophy is beneficial or harmful still remains an
unanswered question. Naturally, the first studies were di-
rected to examination of the pumping efficiency of hearts
demonstrating regression of hypertorphy; they revealed no
impairment in ejection fraction, left ventricular fractional
shortening (14,16) or peak cardiac output (17,18) after re-
duction of left ventricular mass. Neither ejection indexes
nor cardiac output levels are sufficient by themselves to
adequately describe cardiac performance and reserve. How-
ever, few studies have carefully differentiated the effects of
regression of hypertrophy from those of blood pressure con-
trol on those results; it is essential to consider the effects
of alterations in afterload (as evaluated from end-systolic
left ventricular stress, for instance) on changes in cardiac
function before drawing conclusions regarding the conse-
quences of reduction in ventricular mass (7,14). Moreover,
responses to sudden or rapidly developing increases in af-
terload or to different forms of exercise are needed to eval-
uate the heart's ability to withstand the stresses of everyday
life or sudden exacerbations in hypertension. Still undeter-
mined are the effects of regression of hypertrophy on ab-
normalities in diastolic function of the left ventricle that are
common in hypertension and that have recently been re-
ported to correlate with left ventricular mass (9).
Inotropic responses and coronary vascular reo
serve. At more basic levels, left ventricular hypertrophy
has been associated with reductions in inotropic responses
to catecholamines (20) and coronary vascular reserve (21).
Both may playa role in the evolution of heart disease in
ventricular hypertrophy; their responses to therapy still need
further definition. A wide spectrum of alterations at various
points in the adenylate cyclase system has been described
in the myocardium of hypertensive rats (22); progressive
reduction of inotropic response to activators of that system
may rob the hypertrophied ventricle of adrenergic support
and playa role in the eventual progression from hypertrophy
to heart failure. Early reports suggest that some of those
abnormalities may be corrected with regression of left ven-
tricular hypertrophy. Reduction in coronary flow reserve is
seen in severe hypertrophy. Of particular interest in relation
to blood pressure control and changes in left ventricular
mass is the balance that exists between coronary perfusion
pressure and myocardial mass. A reduction in blood pressure
without a concomitant reduction in hypertrophy can upset
this balance and interfere with coronary flow reserve (23).
If confirmed, these observations might have important clin-
ical implications.





Regression of vascular hypertrophy. The question re-
garding coronary flow raises a wider question about the
possibility of regression of vascular hypertrophy by anti-
hypertensive therapy. Vascular lesions playa major role in
the evolution of hypertension and its complications. In-
creased wall thickness of resistance vessels will amplify the
effects of even normal vasconstrictor stimuli on peripheral
resistance, so that vascular hypertrophy will help perpetuate
hypertension (24). Early studies (25) showed a parallelism
between variations in heart weight and indexes of protein
synthesis in the mesenteric arteries of spontaneously hy-
pertensive rats. Reports from Goteborg (26) suggest that
regression of the structural component of peripheral resis-
tance occurs along with reduction of cardiac mass during
antihypertensive treatment in spontaneously hypertensive
rats. However, significant differences in structural response
to hypertension were found between the myocardium and
the aorta.
Implications. All these questions obviously need more
precise answers regarding the importance of modulating
factors, the functional sequelae of regression of left ven-
tricular hypertrophy and the parallelism or divergence be-
tween cardiac and vascular hypertrophy. As the picture be-
comes clearer, with more precise differentiation of various
types of hypertensive disease, there is no doubt that con-
siderations of regression of hypertrophy will be a major
influence in the decision for and choice of therapy.
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